Natasha Daughtrey (Goodwin Procter LLP)

article

Five patent issues that European biosimilar developers should consider before entering the US market

26 June 2020 | By Grace Truong (Goodwin Procter LLP), Joshua Whitehill (Goodwin Procter LLP), Natasha Daughtrey (Goodwin Procter LLP)

As patents on originator biologic medicines begin to expire, there are growing opportunities for biosimilars to enter the market at lower prices. Joshua Whitehill, Natasha Daughtrey and Grace Truong discuss key aspects of US patent law that European developers should consider before entering the American market.

reference

Five patent issues that European biosimilar developers should consider before entering the US market

25 June 2020 | By Grace Truong (Goodwin Procter LLP), Joshua Whitehill (Goodwin Procter LLP), Natasha Daughtrey (Goodwin Procter LLP)

References for 'Five patent issues that European biosimilar developers should consider before entering the US market', in European Pharmaceutical Review Issue 3 2020.